GoldenGolden
Advanced Search
Lilly Asia Ventures

Lilly Asia Ventures

Lilly Asia Ventures or LAV is a venture capital firm investing in biomedical companies.

Lilly Asia Ventures is a venture capital firm. The firm makes venture capital investments in the life sciences and healthcare sectors in Asia, with a focus on China. It was founded in 2008 and is based in Shanghai, China.

Lilly Asia Ventures wants to become the partner for entrepreneurs seeking capital and to build great companies developing products that treat diseases and improve human health.

Lilly Asia Ventures originated as a corporate venture subsidiary of Eli Lilly, until they spun off and became an independent investment management company. They manage over $1.2 billion of committed capital.

Timeline

Associated investment funds

People

Name
Role
LinkedIn

Darren Ji

Venture Partner

Fei Chen

Managing Partner

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Emmy Lucas
September 10, 2021
FierceBiotech
OrbiMed Advisors and Lilly Asia Ventures are two key players pouring money into RNA-targeting technology via ADARx Pharmaceuticals' $75 million series B round. The funding will take the San Diego-based biotech's growing pipeline of RNA-targeting therapeutics into the clinic, ADARx said in a statement on Wednesday.
FinSMEs
May 10, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Alebund Pharmaceuticals
May 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), a biopharmaceutical company dedicated to developing innovative therapies for the...
Regor Therapeutics Group
February 19, 2021
www.prnewswire.com:443
/PRNewswire/ -- Regor Therapeutics, a clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders...
November 27, 2020
BioSpace
Eluminex Biosciences, an Ophthalmology-Focused Biotechnology Company, Announces Closing of $50 Million Series A Financing - read this article along with other careers information, tips and advice on BioSpace
Eluminex Biosciences
November 27, 2020
www.prnewswire.com:443
/PRNewswire/ -- Eluminex Biosciences Limited (Eluminex), an ophthalmic biotechnology company committed to the discovery and development of first-in-class...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.